Astra Zeneca

AstraZeneca's Carbon Emissions and Climate Commitments

AstraZeneca, a pharmaceutical preparation manufacturing company headquartered in GB, is actively engaged in addressing its climate impact. The company is committed to ambitious reduction targets, aiming for net-zero greenhouse gas (GHG) emissions across its value chain by 2045.

Emissions Data:

For the latest reporting year available, 2025, AstraZeneca reported a total of approximately 687.9 million kilograms of CO2e. This total is comprised of:

• Scope 1 Emissions: Approximately 62.6 million kg CO2e.
• Scope 2 Emissions (Market-Based): Approximately 11.3 million kg CO2e.
• Scope 3 Emissions: Approximately 619.8 million kg CO2e.

In 2024, total emissions were approximately 6.09 billion kg CO2e, with Scope 1 emissions at about 125.4 million kg CO2e and Scope 3 emissions at approximately 5.72 billion kg CO2e.

The company's emissions profile shows a significant contribution from Scope 3, with purchased goods and services being a major component, accounting for approximately 3.40 billion kg CO2e in 2025. Use of sold products also represents a substantial portion, at about 1.62 billion kg CO2e in 2025.

Climate Commitments and Reduction Targets:

AstraZeneca has set a series of science-based targets aligned with the goal of limiting global warming to 1.5°C. Key commitments include:

• Near-Term Targets:

  • An ambitious reduction of absolute Scope 1 and 2 GHG emissions by 98% by 2026, using a 2015 baseline. This target has been validated by the Science Based Targets initiative (SBTi).
  • A commitment to achieve 100% renewable electricity consumption globally by 2025.
  • A pledge to transition to an entirely electric road fleet by the end of 2025.
  • A target to reduce absolute Scope 3 GHG emissions by 50% by 2030 from a 2019 baseline. Specific Scope 3 categories also have reduction targets, such as a 95% reduction for the use of sold products by 2030.

• Long-Term Targets:

  • A commitment to achieve net-zero GHG emissions across the entire value chain by 2045.
  • A further goal to reduce absolute Scope 3 GHG emissions by 90% by 2045 from a 2019 baseline.

AstraZeneca is also focused on engaging its supply chain, with a commitment that 95% of its suppliers by spend (covering purchased goods and services and capital goods) will have science-based targets by 2025. Furthermore, they are working towards a carbon-negative value chain by 2030. The company is also developing next-generation propellants for its inhaled medicines with near-zero global warming potential.